Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License PaymentAccesswire · Sep 30, 2026
Ainos Completes Delivery of 1,400 AI Nose Systems to ASE Under $2.1 Million, Three-Year ContractAccesswire · Sep 29, 2026
Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical IntelligenceAccesswire · Sep 28, 2026
Ainos, Inc. (NASDAQ:AIMD) Shares Shorted: Short Interest Up 172.6% in SeptemberDefense World · Sep 27, 2026
Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration FrameworkAccesswire · Sep 24, 2026 Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds.